Revision to Previously Issued Consolidated Financial Statements (Revisions On Previously Issued Consolidated Statement Of Cash Flow) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		12 Months Ended
	Dec. 31, 2011		Dec. 31, 2012	Dec. 31, 2011		Dec. 31, 2010
Net income	$ 11,550	[1],[2]	$ 9,620	$ 28,122		$ 21,081
Deferred taxes, net			(6,785)	(1,602)
Accounts receivable, net			356	(2,730)	[3]	(9,277)
Inventories			801	(2,269)	[3]	3,115
Accrued and other current liabilities			3,070	3,680		2,199
Scenario, Previously Reported [Member]
Net income	12,402			28,464
Deferred taxes, net				(1,241)
Accounts receivable, net				(3,907)	[3]
Inventories				(1,665)	[3]
Accrued and other current liabilities				$ 3,550

[1] For the three months ended December 31, 2011, the restatement revisions had an impact of decreasing revenues, cost of product sales, and net income by $1.8 million, $0.9 million, and $0.9 million, respectively, and decreasing basic and diluted earnings per share by $0.01 and $0.02, respectively.

[2] Changes to the selected quarterly financial data for the three months ended December 31, 2011 mainly related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.

[3] Changes to net cash used in accounts receivable and inventory mainly related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.